Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment.

Wang X, Blanchard J, Grundke-Iqbal I, Iqbal K.

PLoS One. 2015 Dec 23;10(12):e0145441. doi: 10.1371/journal.pone.0145441. eCollection 2015.

2.

Sera from children with autism induce autistic features which can be rescued with a CNTF small peptide mimetic in rats.

Kazim SF, Cardenas-Aguayo Mdel C, Arif M, Blanchard J, Fayyaz F, Grundke-Iqbal I, Iqbal K.

PLoS One. 2015 Mar 13;10(3):e0118627. doi: 10.1371/journal.pone.0118627. eCollection 2015.

3.

Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.

Wang X, Blanchard J, Tung YC, Grundke-Iqbal I, Iqbal K.

J Alzheimers Dis. 2015;45(2):423-35. doi: 10.3233/JAD-142403.

PMID:
25589718
4.

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.

Dai CL, Chen X, Kazim SF, Liu F, Gong CX, Grundke-Iqbal I, Iqbal K.

J Neural Transm (Vienna). 2015 Apr;122(4):607-17. doi: 10.1007/s00702-014-1315-y. Epub 2014 Sep 19.

PMID:
25233799
5.

Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.

Arif M, Wei J, Zhang Q, Liu F, Basurto-Islas G, Grundke-Iqbal I, Iqbal K.

J Biol Chem. 2014 Oct 3;289(40):27677-91. doi: 10.1074/jbc.M114.565358. Epub 2014 Aug 15.

6.

Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam.

Arif M, Kazim SF, Grundke-Iqbal I, Garruto RM, Iqbal K.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1144-9. doi: 10.1073/pnas.1322614111. Epub 2014 Jan 6.

7.

Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection.

Wang X, Blanchard J, Grundke-Iqbal I, Wegiel J, Deng HX, Siddique T, Iqbal K.

Acta Neuropathol. 2014 Feb;127(2):243-56. doi: 10.1007/s00401-013-1175-9. Epub 2013 Oct 18.

8.

Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.

Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K.

J Biol Chem. 2013 Jun 14;288(24):17495-507. doi: 10.1074/jbc.M112.446070. Epub 2013 May 2.

9.

CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease.

Jin N, Qian W, Yin X, Zhang L, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F.

Nucleic Acids Res. 2013 Mar 1;41(5):3240-56. doi: 10.1093/nar/gks1227. Epub 2013 Jan 22.

10.

Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures.

Cardenas-Aguayo Mdel C, Kazim SF, Grundke-Iqbal I, Iqbal K.

PLoS One. 2013;8(1):e53596. doi: 10.1371/journal.pone.0053596. Epub 2013 Jan 8.

11.

Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease.

Chen Y, Tian Z, Liang Z, Sun S, Dai CL, Lee MH, LaFerla FM, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

PLoS One. 2012;7(12):e51432. doi: 10.1371/journal.pone.0051432. Epub 2012 Dec 7.

12.

A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse).

Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

Mol Neurobiol. 2013 Apr;47(2):711-25. doi: 10.1007/s12035-012-8375-5. Epub 2012 Nov 14.

13.

Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain.

Liu Y, Li X, Yu Y, Shi J, Liang Z, Run X, Li Y, Dai CL, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

PLoS One. 2012;7(8):e43724. doi: 10.1371/journal.pone.0043724. Epub 2012 Aug 22.

14.

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion.

Yin X, Jin N, Gu J, Shi J, Zhou J, Gong CX, Iqbal K, Grundke-Iqbal I, Liu F.

J Biol Chem. 2012 Aug 31;287(36):30497-506. doi: 10.1074/jbc.M112.355412. Epub 2012 Jul 5.

15.

Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.

Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K.

J Alzheimers Dis. 2013;33 Suppl 1:S123-39. Review.

PMID:
22710920
16.

Diverse regulation of AKT and GSK-3β by O-GlcNAcylation in various types of cells.

Shi J, Wu S, Dai CL, Li Y, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX.

FEBS Lett. 2012 Jul 30;586(16):2443-50. doi: 10.1016/j.febslet.2012.05.063. Epub 2012 Jun 8.

17.

Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.

Yu Y, Zhang L, Li X, Run X, Liang Z, Li Y, Liu Y, Lee MH, Grundke-Iqbal I, Iqbal K, Vocadlo DJ, Liu F, Gong CX.

PLoS One. 2012;7(4):e35277. doi: 10.1371/journal.pone.0035277. Epub 2012 Apr 19.

18.

An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide.

Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K.

Acta Neuropathol. 2012 Jan;123(1):133-51. doi: 10.1007/s00401-011-0908-x. Epub 2011 Nov 15.

19.

Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome.

Blanchard J, Bolognin S, Chohan MO, Rabe A, Iqbal K, Grundke-Iqbal I.

J Neuropathol Exp Neurol. 2011 Dec;70(12):1070-9. doi: 10.1097/NEN.0b013e318236e9ad.

PMID:
22082658
20.

Opportunities and challenges in developing Alzheimer disease therapeutics.

Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2011 Nov;122(5):543-9. doi: 10.1007/s00401-011-0878-z. Epub 2011 Sep 30. Review.

PMID:
21959585
21.

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Rockenstein E, Ubhi K, Doppler E, Novak P, Moessler H, Li B, Blanchard J, Grundke-Iqbal I, Iqbal K, Mante M, Adame A, Crews L, Masliah E.

J Alzheimers Dis. 2011;27(4):743-52. doi: 10.3233/JAD-2011-110914.

22.

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, Iqbal K.

FEBS Lett. 2011 Sep 2;585(17):2653-9. doi: 10.1016/j.febslet.2011.07.020. Epub 2011 Jul 28.

23.

Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes.

Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX.

J Pathol. 2011 Sep;225(1):54-62. doi: 10.1002/path.2912. Epub 2011 May 19.

24.

Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease.

Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, Iqbal K.

J Alzheimers Dis. 2011;25(3):505-15. doi: 10.3233/JAD-2011-101959.

25.

Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A.

Qian W, Liang H, Shi J, Jin N, Grundke-Iqbal I, Iqbal K, Gong CX, Liu F.

Nucleic Acids Res. 2011 Aug;39(14):6161-71. doi: 10.1093/nar/gkr195. Epub 2011 Apr 5.

26.

Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease.

Shi J, Qian W, Yin X, Iqbal K, Grundke-Iqbal I, Gu X, Ding F, Gong CX, Liu F.

J Biol Chem. 2011 Apr 22;286(16):14639-48. doi: 10.1074/jbc.M110.204453. Epub 2011 Mar 2.

27.

Splicing factor SC35 promotes tau expression through stabilization of its mRNA.

Qian W, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F.

FEBS Lett. 2011 Mar 23;585(6):875-80. doi: 10.1016/j.febslet.2011.02.017. Epub 2011 Feb 17.

28.

Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A.

Ding S, Shi J, Qian W, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F.

Neurobiol Aging. 2012 Jul;33(7):1389-99. doi: 10.1016/j.neurobiolaging.2010.11.021. Epub 2011 Jan 6.

29.

Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease.

Qian W, Yin X, Hu W, Shi J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX, Liu F.

J Alzheimers Dis. 2011;23(4):617-27. doi: 10.3233/JAD-2010-100987.

30.

Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice.

Blanchard J, Chohan MO, Li B, Liu F, Iqbal K, Grundke-Iqbal I.

J Alzheimers Dis. 2010;21(4):1185-95. doi: 10.3233/JAD-2010-1000069.

PMID:
20952820
31.

Alzheimer's disease, a multifactorial disorder seeking multitherapies.

Iqbal K, Grundke-Iqbal I.

Alzheimers Dement. 2010 Sep;6(5):420-4. doi: 10.1016/j.jalz.2010.04.006.

32.

Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.

Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2010 Nov;120(5):605-21. doi: 10.1007/s00401-010-0734-6. Epub 2010 Aug 10.

PMID:
20697724
33.

Tau in Alzheimer disease and related tauopathies.

Iqbal K, Liu F, Gong CX, Grundke-Iqbal I.

Curr Alzheimer Res. 2010 Dec;7(8):656-64. Review.

34.

Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration.

Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, Iqbal K.

J Biol Chem. 2010 Oct 1;285(40):30851-60. doi: 10.1074/jbc.M110.110957. Epub 2010 Jul 27.

35.

Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial.

Iqbal K, Wang X, Blanchard J, Liu F, Gong CX, Grundke-Iqbal I.

Biochem Soc Trans. 2010 Aug;38(4):962-6. doi: 10.1042/BST0380962. Review.

36.

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K.

FASEB J. 2010 Nov;24(11):4420-32. doi: 10.1096/fj.10-158477. Epub 2010 Jul 22.

37.

Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice.

Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I.

FEBS Lett. 2010 Aug 4;584(15):3359-65. doi: 10.1016/j.febslet.2010.06.025. Epub 2010 Jun 30.

38.

Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.

Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K.

Neurosci Lett. 2010 Jul 12;478(3):179-83. doi: 10.1016/j.neulet.2010.05.012. Epub 2010 May 12.

39.

Targeting tau protein in Alzheimer's disease.

Gong CX, Grundke-Iqbal I, Iqbal K.

Drugs Aging. 2010 May;27(5):351-65. doi: 10.2165/11536110-000000000-00000. Review.

PMID:
20450234
40.

PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta.

Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F.

J Alzheimers Dis. 2010;19(4):1221-9. doi: 10.3233/JAD-2010-1317.

PMID:
20308788
41.

Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.

Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K.

Clin Chem. 2009 Dec;55(12):2171-9. doi: 10.1373/clinchem.2009.130286. Epub 2009 Oct 22.

42.

Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.

Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX.

Am J Pathol. 2009 Nov;175(5):2089-98. doi: 10.2353/ajpath.2009.090157. Epub 2009 Oct 8.

43.

Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide.

Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I.

Neurobiol Aging. 2011 Aug;32(8):1420-34. doi: 10.1016/j.neurobiolaging.2009.08.008. Epub 2009 Sep 19.

PMID:
19767127
44.

Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX.

J Neurochem. 2009 Oct;111(1):242-9. doi: 10.1111/j.1471-4159.2009.06320.x. Epub 2009 Jul 31.

45.

Novel therapeutic strategies for neurodegenerative disease.

Tanimukai H, Kudo T, Tanaka T, Grundke-Iqbal I, Iqbal K, Takeda M.

Psychogeriatrics. 2009 Jun;9(2):103-9. doi: 10.1111/j.1479-8301.2009.00289.x. Review.

46.

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX.

Brain. 2009 Jul;132(Pt 7):1820-32. doi: 10.1093/brain/awp099. Epub 2009 May 18.

47.

Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage.

Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX.

J Alzheimers Dis. 2009;17(3):531-9. doi: 10.3233/JAD-2009-1069.

48.

Anesthesia induces phosphorylation of tau.

Run X, Liang Z, Zhang L, Iqbal K, Grundke-Iqbal I, Gong CX.

J Alzheimers Dis. 2009;16(3):619-26. doi: 10.3233/JAD-2009-1003.

49.

Mechanisms of tau-induced neurodegeneration.

Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I.

Acta Neuropathol. 2009 Jul;118(1):53-69. doi: 10.1007/s00401-009-0486-3. Epub 2009 Jan 30. Review.

50.

Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX.

J Neurochem. 2009 Mar;108(6):1480-94. doi: 10.1111/j.1471-4159.2009.05882.x. Epub 2009 Jan 13.

Supplemental Content

Loading ...
Support Center